B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley Financial Inc. received more demands for information from federal regulators about its dealings with now-bankrupt ...

President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.

I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...

The deferral affects B. Riley’s 6.875% Series A and 7.375% Series B preferred stock, according to a statement Monday. Dividends on those preferreds cost the company $2 million in the second ...